Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 7/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 6/20 | 0.34 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30983954 | 0.94 | PLA2G2A (0.39) | PLA2G2APIK3CDCNR1CNR2ALOX5AP | |
| SCHEMBL30984034 | 0.91 | PIK3CD (0.37) | PIK3CDCNR1CNR2KMT2A | |
| SCHEMBL30983502 | 0.91 | NPC1 (0.38) | PIK3CDCNR1CNR2KMT2AAKT1 | |
| SCHEMBL30983512 | 0.91 | KMT2A (0.36) | PIK3CDCNR1CNR2KMT2A | |
| SCHEMBL31321937 | 0.89 | PLA2G2A (0.40) | PLA2G2APIK3CD | |
| SCHEMBL31269290 | 0.89 | PIK3CD (0.37) | PLA2G2APIK3CDCNR1CNR2 | |
| SCHEMBL30983449 | 0.88 | ALDH1A1 (0.42) | PIK3CDKMT2A | |
| SCHEMBL31321972 | 0.88 | PIK3CD (0.38) | PIK3CDCNR1CNR2 | |
| SCHEMBL30983539 | 0.88 | PIK3CD (0.37) | PIK3CDCNR1CNR2 | |
| SCHEMBL30983817 | 0.88 | CNR1 (0.41) | PIK3CDCNR1CNR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366615-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | PLA2G2A 2236/4885PIK3CD 434/4885CNR1 4278/4885 |
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | PLA2G2A 2236/4885PIK3CD 434/4885CNR1 4278/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | PLA2G2A 2236/4885PIK3CD 434/4885CNR1 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.